Botulinum Toxin or Filler for Smoker's Lines?

What this comparison can and cannot answer

Smoker's lines, also called perioral lines or vertical lip lines, can be visible only during movement, remain visible at rest, or involve both. That distinction matters because botulinum toxin and dermal filler have different treatment objectives. Botulinum toxin is used to reduce selected muscle activity. Filler is used to add support or volume in selected tissue planes. In practice, a plan may also involve no injectable treatment, or a staged approach, but this page compares the two injectable approaches rather than treating either as a default answer.

The comparison below is designed for a consultation discussion, not for self-selection or a diagnosis. The source trail prioritises safety information from the Medicines and Healthcare products Regulatory Agency, known as the MHRA, and patient-safety material from the United States Food and Drug Administration, known as the FDA. It also reflects a recurring limitation in the published clinical literature: studies of treatment specifically for perioral lines are often small, use differing techniques and outcome measures, and do not make a single result transferable to every lip area.

For a fuller definition of the concern, read Cosmetic Journal's smoker's lines guide. Its treatments section gives wider context for injectable and non-injectable categories, while safety and recovery and before you book cover practical preparation and aftercare questions. This page narrows the question to what each injectable approach is trying to change, what may be seen during recovery, and where uncertainty remains.

Editorial selection rule: compare an approach only against criteria a person can observe or discuss: line behaviour, expected visible change, early recovery, recognised risks, reversibility considerations and uncertainty in the evidence. A technique is not ranked.

Side-by-side evidence comparison

The table separates a treatment goal from a guaranteed outcome. "Evidence uncertain" does not mean a treatment cannot be used. It means that published evidence does not support a precise prediction for an individual with a particular pattern of lines. The FDA information cited here is used for recognised safety framing, not as a statement about UK licensing or about a particular plan for the lip area. The MHRA source is used for its general warnings about dermal filler safety.

Source trail reviewed for this table: MHRA dermal filler safety information and FDA botulinum toxin safety and patient-information materials. These sources are strongest for recognised hazards and mechanisms. They are not a substitute for a clinical examination, and they do not supply a head-to-head outcome trial for every perioral presentation.

What outcome is realistic for each approach?

Botulinum toxin is generally discussed when movement repeatedly creases the skin above the lip. Its intended change is a moderation of selected movement, not the removal of the skin's texture, sun-related change or every etched line. Around the mouth, that distinction is especially important. The muscles in this area contribute to speech, drinking, eating, smiling and lip position. A visible reduction in wrinkling may therefore need to be balanced against the possibility of unwanted functional change. The FDA's safety materials describe botulinum toxin's effect on muscle activity and warn about weakness-related adverse effects; they do not provide a universal outcome for smoker's lines.

Dermal filler is generally discussed when lines remain apparent without pursing, or when loss of support is thought to be part of the appearance. The intended change is local support or softening, rather than a change to muscle movement. A line can still be visible after filling, especially where skin quality, repeated movement and anatomy all contribute. Filler can also look temporarily fuller during the early period, so an immediate mirror check is not a reliable final assessment.

Neither method has a credible promise of making the upper-lip area look as though it has never moved or aged. Asking what feature is being targeted is more useful than asking which treatment is universally stronger. A consultation can distinguish lines seen only in animation, lines visible at rest, lip border changes, asymmetry, and texture changes. It can also establish whether the desired degree of change could interfere with normal expression or oral function.

Recovery: what to watch in the first days and weeks

Recovery is not identical to outcome. Bruising, redness, swelling and tenderness may be temporary injection effects with either approach. Their extent is affected by individual factors and by the procedure itself, so a comparison cannot turn them into a precise forecast. Photographs taken in consistent light before treatment and then at agreed intervals can be more useful than repeatedly judging the area in changing mirrors or lighting.

After botulinum toxin, the practical question is often whether movement is changing as intended without creating difficulty. Because the mouth is a high-function area, changes in articulation, sipping, using a straw, smiling or lip seal should be recorded and raised with the treating service. FDA safety warnings make clear that swallowing, speaking or breathing symptoms should not be ignored. A planned review point allows the visible effect and function to be considered together rather than treating appearance as the only outcome.

After filler, swelling and bruising can obscure the early appearance. More importantly, a person should know the urgent warning signs before leaving the appointment. The MHRA identifies serious complications of dermal fillers, including tissue damage and blindness. Severe or escalating pain, skin that turns pale, mottled, dusky or unusually cool, and any visual disturbance are not wait-and-see symptoms. Contact the treating service immediately and seek urgent medical assessment where advised.

Three signs to phone today: new difficulty with swallowing, speaking or breathing after botulinum toxin; severe or worsening pain after filler; or a change in skin colour or vision after filler. These signs are not a diagnosis, but they warrant prompt escalation.

Risks that change the conversation

Risk is not a single list that applies equally to both approaches. With botulinum toxin around the mouth, the key trade-off is that reducing movement can unintentionally affect movement needed for everyday tasks. A subtle change may be unwelcome even if it is not medically dangerous. FDA information warns that botulinum toxin effects can extend beyond the injection site and identifies symptoms that need urgent medical attention. It is therefore relevant to disclose any condition, medicine or prior reaction that may alter risk, rather than assuming a previous treatment elsewhere predicts this treatment's safety.

With dermal filler, the issue that needs explicit discussion is vascular compromise. This refers to interrupted blood supply and is a medical urgency because tissue can be damaged. The MHRA warns of serious complications from dermal fillers, including tissue damage and blindness. The possibility is uncommon in comparison with minor local effects, but a low frequency does not make the response plan optional. Before treatment, a person can ask what symptoms should trigger direct contact, how urgent concerns are handled, and what emergency pathway is used.

Both approaches can involve bruising, swelling, discomfort, asymmetry or dissatisfaction with appearance. Those outcomes do not automatically show that something dangerous has happened, but they deserve a defined review route. It is also sensible to distinguish a known short-term effect from a result that is changing rapidly, painful or functionally disruptive. Cosmetic Journal's safety and recovery coverage explains why the timing and pattern of a symptom matter as much as the symptom's name.

A decision rule to take into a consultation

The decision is not "toxin versus filler" in the abstract. It is whether the proposed objective matches the pattern of lines, whether the likely trade-off is acceptable, and whether the safety plan is clear. This rule is deliberately conservative because a photograph, a social-media result or another person's treatment cannot establish anatomy, movement or medical suitability.

1. If lines are mainly created by pursing or other movement, ask whether reducing selected movement is the stated objective, and ask what effect on speaking, drinking and smiling is possible.
2. If lines remain visible at rest, ask whether local support is the stated objective, what early swelling may obscure, and how the result will be reviewed once it has settled.
3. If both movement and static lines matter, ask whether treating one element first would make the trade-off clearer. Do not assume combining approaches is necessary or that it will erase all lines.
4. If the proposed outcome is described in absolute terms, pause. The available safety sources and variable clinical evidence do not support a promise of complete removal, symmetry or a fixed duration for every smoker's-line presentation.
5. If urgent signs and follow-up are not explained, do not treat the plan as complete. A recovery plan should state who to contact and what symptoms require same-day escalation.

The main limit of this page is scope. It does not assess practitioners, identify treatment venues, compare products, give dosing or injection maps, or replace individual medical advice. It does not apply to people with urgent symptoms, who should seek immediate clinical help. It also does not cover resurfacing, surgical procedures, skincare or the broader causes of perioral ageing. For those topics, use the site's treatments and before-you-book sections as starting points rather than reading this comparison as a complete treatment plan.